SCHEMBL256941

SCHEMBL256941

Cc1nn2c(-c3ccccc3)cc(Cl)nc2c1-c1ccc2c(c1)OCO2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.55
▸ MAPT P10636 10/20 0.53
▸ MAPK1 P28482 2/20 0.48
▸ NPC1 O15118 5/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ RAB9A P51151 4/20 0.43
▸ FYN P06241 1/20 0.43
▸ MAT2A P31153 1/20 0.42
▸ HPGD P15428 2/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ ADORA3 P0DMS8 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15121459 0.82 TP53 (0.46) TP53MAPTNPC1NPSR1SMN1; SMN2
SCHEMBL15020632 0.81 TP53 (0.79) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL15042157 0.81 TP53 (0.67) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL257698 0.77 MAPT (0.78) TP53MAPTMAPK1NPC1NPSR1
Pyrimidine SCHEMBL15020679 0.77 TP53 (0.41) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL15020929 0.76 ALDH1A1 (0.45) TP53MAPTMAPK1SMN1; SMN2FYN
SCHEMBL10072102 0.75 PLAT (0.46) TP53MAPTMAPK1NPC1SMN1; SMN2
SCHEMBL257514 0.75 MAPT (0.60) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL256922 0.72 TP53 (0.65) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL257542 0.72 TP53 (0.55) TP53MAPTMAPK1NPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 TP53 4550/4885MAPT 2617/4885MAPK1 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback